Current Behavioral Neuroscience Reports, Journal Year: 2025, Volume and Issue: 12(1)
Published: Jan. 30, 2025
Language: Английский
Science Signaling, Journal Year: 2024, Volume and Issue: 17(856)
Published: Oct. 1, 2024
Alzheimer's disease (AD) is a progressive neurodegenerative characterized by amyloid plaques and cognitive decline, the latter of which thought to be driven soluble oligomeric amyloid-β (oAβ). The dysregulation G protein-gated inwardly rectifying K
Language: Английский
Citations
4
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(20), P. 11223 - 11223
Published: Oct. 18, 2024
As the global population ages, incidence of neurodegenerative diseases such as Alzheimer’s and Parkinson’s is rapidly rising. These present a significant public health challenge, they severely impair cognitive motor functions, ultimately leading to substantial reduction in quality life placing heavy burden on healthcare systems worldwide. Although several therapeutic agents have been developed manage symptoms these diseases, their effectiveness often limited, there remains an urgent need for preventive strategies. Growing evidence indicates that bioactive compounds from natural products possess neuroprotective properties through antioxidant anti-inflammatory effects, modulating key pathways phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) brain-derived neurotrophic factor–tropomyosin receptor B–cAMP response element-binding protein (BDNF-TrkB-CREB), which are crucial neuronal survival. may also reduce amyloid-beta tau pathology, well enhance cholinergic neurotransmission by inhibiting acetylcholinesterase activity. By targeting oxidative stress, neuroinflammation, neurodegeneration, offer promising approach both prevention treatment. findings suggest be preventing treating diseases. This review aims explore pathogenesis limitations current therapies, potential role agents.
Language: Английский
Citations
4
Pharmaceutical Chemistry Journal, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 21, 2025
Language: Английский
Citations
0
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16
Published: Jan. 29, 2025
Alzheimer’s disease (AD) is one of the most common diseases central nervous system in middle-aged and elderly population. It a neurodegenerative disorder, its main clinical symptoms include loss established memories, decline learning capacity, buildup β-amyloid peptides. The often accompanied by changes formation neurofibrillary tangles. However, number drugs available for treatment AD remains limited. Currently, existing medications are not effective completely curing or stopping progression. Due to their excellent biocompatibility biodegradability, polymers have been widely used as drug delivery carriers various fields including cancer therapy wound healing. use enables targeted prolonged release profiles. In recent years, researchers made significant progress utilizing such polyethylene glycol, poly (lactic-co-glycolic acid) (PLGA), chitosan (CS) deliver blood-brain barrier receptor ligands AD. Moreover, many with inherent therapeutic properties developed, already marketed GV-971 well experimental PLGA CS oligosaccharide. This review summarizes applications over past few years highlights current limitations help better understand advancements polymer development identify future research directions.
Language: Английский
Citations
0
Current Behavioral Neuroscience Reports, Journal Year: 2025, Volume and Issue: 12(1)
Published: Jan. 30, 2025
Language: Английский
Citations
0